Organon & Co. (OGN)

NYSE Currently up 0.04 (+0.33%) in today's trading session

1 member of Congress has disclosed 1 trade in Organon & Co. (OGN) via STOCK Act filings. The most recent disclosure was filed by Kevin Hern on 3 June 2021.

Organon & Co. is currently trading at $13.56, positioned at 100% of its 52-week range ($5.69 – $13.60).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Free asset at sign up • Eligible regions only
Live portfolio tracking
Automatic rebalancing

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Not available in the US.

Past Performance is not an indication of future results.

*Free asset promotion available at sign up in eligible regions only. Terms and conditions apply.

Current Price
$13.56
24h Change
+0.04 (+0.33%)
52 Week Range
$5.69$13.60
View on NASDAQ

Organon & Co. Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for OGN

Select to highlight on chart
0 transactions
Compliance: 0%
No data

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$3.56B

Volume

2.1M

Beta

1.54

P/E Ratio

4.05

Fundamentals

EPS

$3.35

Div. Yield

0.59%

Open

$13.51

Day Range

$13.51 — $13.57

Company Information

Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NYSE · USD
Country
US
CEO
Joseph T. Morrissey Jr.
IPO Date
2021-05-14

Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments,...

Earnings

Next Report

Q2 2026

4 Aug

EPS Est.

$0.87

Rev. Est.

$1.6B

Days Until

12

Recent Quarters

Q1 202630 Apr
EPS$0.71
Miss 14.5%
Q4 202512 Feb
EPS$0.63
Miss 13.7%
Q3 202510 Nov
EPS$1.01
Beat 8.6%
Q2 20255 Aug
EPS$1.00
Beat 6.4%
Q1 20251 May
EPS$1.02
Beat 14.6%
Q4 202413 Feb
EPS$0.90
Miss 2.2%
Q3 202431 Oct
EPS$0.87
Miss 3.3%
Q2 20246 Aug
EPS$1.12
Beat 5.7%
Q1 20242 May
EPS$1.22
Beat 25.8%
Q4 202315 Feb
EPS$0.88
Beat 10.0%
Q3 20232 Nov
EPS$0.87
Miss 16.4%
Q2 20238 Aug
EPS$1.31
Beat 35.0%
Q1 20234 May
EPS$1.08
Miss 8.5%
Q4 202216 Feb
EPS$0.81
Miss 4.7%
Q3 20223 Nov
EPS$1.32
Beat 17.9%
Q2 20224 Aug
EPS$1.25
Beat 7.8%
Q1 20225 May
EPS$1.65
Beat 26.9%
Q4 202117 Feb
EPS$1.37
Beat 9.6%
Q3 202111 Nov
EPS$1.67
Beat 16.0%
Q2 202112 Aug
EPS$1.72
Beat 22.9%
Q1 202121 Jun
EPS$1.58
Beat 4.0%
Q4 202017 Mar
EPS$2.16
Q3 202031 Dec
EPS$1.45
Q1 202030 Jun
EPS$2.14
Q4 201931 Mar
EPS$2.78

Dividends

Dividend History

11 May 2026
Amount $0.0200
23 Feb 2026
Amount $0.0200
20 Nov 2025
Amount $0.0200
15 Aug 2025
Amount $0.0200
12 May 2025
Amount $0.0200
24 Feb 2025
Amount $0.2800
12 Nov 2024
Amount $0.2800
16 Aug 2024
Amount $0.2800
10 May 2024
Amount $0.2800
23 Feb 2024
Amount $0.2800
10 Nov 2023
Amount $0.2800
17 Aug 2023
Amount $0.2800
12 May 2023
Amount $0.2800
24 Feb 2023
Amount $0.2800
10 Nov 2022
Amount $0.2800
12 Aug 2022
Amount $0.2800
13 May 2022
Amount $0.2800
25 Feb 2022
Amount $0.2800
19 Nov 2021
Amount $0.2800
20 Aug 2021
Amount $0.2800

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations
No similar stocks found
No congressional trading patterns available for recommendations

Frequently Asked Questions about OGN

Which members of Congress have traded OGN?
1 member of Congress has disclosed 1 trade in Organon & Co. (OGN) under the STOCK Act: Kevin Hern.
When was OGN most recently disclosed by Congress?
The most recent OGN disclosure was filed by Kevin Hern on 3 June 2021.
How can I track new congressional trades in OGN?
This OGN page updates as soon as new STOCK Act disclosures are filed for Organon & Co.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
© 2026 - All rights reserved. Powered by Vantara Labs
This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.